U-M Center for Drug Repurposing searches for coronavirus therapy
Launched late last year, the U-M Center for Drug Repurposing (UM-CDR) is already taking on the challenge of finding a drug previously approved by the FDA — or more likely a cocktail of several drugs — to battle COVID-19, the illness caused by the novel coronavirus.
A joint venture of the Michigan Institute for Clinical & Health Research (MICHR) and the Life Sciences Institute, the UM-CDR is led by Jonny Sexton, George Mashour and Kevin Weatherwax. The UM-CDR mobilized its resources to begin rapidly identifying and screening drugs from their library of thousands that are most likely to be effective as therapeutic interventions for COVID-19 in the clinical setting.
Assisted by artificial intelligence methods, the U-M team will begin screening all 2,400 FDA approved drugs and will extend screening to experimental compounds from a library of nearly 7,000 compounds in search of an antiviral drug or drug cocktail that is effective against COVID-19.